The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

The Directors: New directors Herbst and Gius chart a future built on AI, collaboration, and rural access

Cancer Policy

Senate leaders introduce revised, bipartisan stopgap bill that would ban OMB from finalizing rule that would politicize science

Federal judge declines to block Medicaid work requirements

HRSA redrafts 340B rebate pilot program after courts block the original version

Johnson and Johnson reaches $5.5B settlement deal over talc lawsuits

FDA’s OCE publishes three final guidances to increase clinical trial enrollment

HHS releases government-wide policy to prohibit gain-of-function research

Clinical Roundup

Phase III XPORT-EC-042 trial in endometrial cancer does not meet primary endpoint

BRCA-negative patients may still be high-risk for breast cancer, study finds

DELFI liquid biopsy detects liver cancer across diverse international populations, Hopkins-led study finds

Mesothelioma cells rewire genes to resist GNE-7883, study finds

Biobank of tumor models reveals cancers’ weak spots, Nature study finds

Anti-Müllerian hormone may help many women with HR+ breast cancer avoid chemotherapy

In The Clinic
Trials & Tribulations

Retraction is not refutation: Why chrono-immunotherapy still deserves scientific investigation

Trials & Tribulations
Trials & Tribulations
FreeTrials & Tribulations

The Cancer Letter is an independent weekly news publication and the leading source for information on the issues that shape oncology.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account